2022-08-31-麦肯锡-2028展望_中国如何影响全球生物制药行业Vision_2028_How_China_could_impact_the_global_biopharma_industry_46页_2mb

China's biopharma industry is poised to increase its global influence by 2028, according to a McKinsey report analyzing key factors and scenarios. The report highlights that China's advancements in manufacturing, funding, and cross-border transactions are driving this growth, but challenges such as regulatory hurdles, clinical data acceptance, and innovation gaps remain. The analysis predicts three impact scenarios: Continued Momentum (most likely), where China integrates into the global biopharma value chain with gradual progress; Stunted Impact (possible if geopolitical tensions worsen), leading to limited market access; and Transformative Impact (less likely), where China emerges as a global leader. Key recommendations emphasize building partnerships, navigating capital challenges, and focusing on unmet patient needs. Overall, China's role in biopharma could enhance global innovation and patient access, particularly in developing economies.

• Promising Areas: Growth in CDMOs, AIDD, and affordable therapies.
• Challenges: Achieving global regulatory standards and closing the gap in breakthrough innovations.
• Scenarios: Predictions vary from cautious growth to potential setbacks based on external factors.